focu beyond initi coverag
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag under-perform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
initi coverag outperform rate target price
prolong courtship closer fruition rais target price
 plenti afraid use rais estim
brick lower estim target price
vision announc robust capit alloc plan
look driver upsid upcom investor commun meet
incom ceo provid perspect prioriti ahead take top role
beyond parti line cfo transit
us card novemb trust loss modestli m/m better histor
consum credit qualiti master trust macroeconom data updat
interest rate excess reserv cs
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
infrastructur action egress enb investor day midstream thought
 mich sentiment dec cs estimate
 mich yr inflat dec cs
 mich yr inflat dec
receiv product pleas specifi credit suiss contact email call
near-term bounc like volatil subsid
sinc late septemb volatil doubl drive stock price histori show month
follow spike vix equiti tend deliv outsiz return
experienc above-trend ep growth driven tax chang govern stimulu non-recur
item like see deceler toward sustain trend level ep growth
importantli recess risk well-contain backdrop suffici propel market
market expect confirm jerom powel recent comment approach neutral fed fund rate
indic first countri renorm zero-r polici believ complet process
meaning catalyst market upsid
 year-end
revis year-end price target repres upsid current level
keep ep estim unchang impli ep growth
expect trajectori ep economi remain virtual unchang recent market disrupt
lower price target reflect recent volatil rather chang fundament backdrop
focu beyond initi coverag
initi coverag medic suppli devic ms stock
outperform rate ew
medic suppli devic ms fall four major categori
under-perform rate
devic rang highli differenti clinical-data-driven devic transcathet heart valv rel
equip rang beds/stretch advanc robot surgeri system advanc imaging/diagnost
suppli catch-al categori consum tube drape replac blade nutrit pharmaceut
solut pre-fil syring anesthesia etc
servic clinic support train
examin valu creation identifi area think investor focu increment dollar market
valu creat given segment next year key metric combin potenti growth address
scale end-market three segment view occupi valu creation sweet spot structur
heart sh robot surgeri rs diabet expect forefront next wave disrupt
ms come year sh rs diabet grown scale meaning enough drive substanti
dollar sale growth market sweet spot early- mid-stag high-growth phase ms
life-cycle least sever year runway ahead steep segment ms s-curv slide
sh therapi technolog heart valv repair replac sh driven primarili disrupt open-
heart surgeri minim invas devic sh current bil market expect grow compound-annual-growth-rate
bil
rs robot advanc surgic technolog improv precis reduc invas surgeri rs driven
primarili convers convent surgeri robotically-assist procedur rs current bil market
expect grow compound-annual-growth-rate bil
diabet mobil devic use manag blood glucos level driver includ rapidli innov devic
increas afford reimburs diabet current bil market expect grow compound-annual-growth-rate
bil
receiv product pleas specifi credit suiss contact email call
initi coverag outperform rate target price
fire cylind abbott new product drive improv organ growth mix return
deliv organ revenu growth last four quarter prior four quarter driven
new product success execut integr stj alr see larg number posit catalyst
growth driver next month extend gain
leadership new product high-growth devic market addit fuel revenu growth new product
high-growth market structur heart sh diabet implant cardiac monitor abbott also remain
leader afib neuromod addit recent destin therapi approv heartmat return
lvad busi above-market growth
half revenu growth compani emerging- high-growth busi estim compani
emerging- high-growth busi gener nearli half revenu growth although
busi less total sale
market stabil wamgr go higher stabil growth nutrit steadi intermediate- long-
term growth establish pharma diagnost enabl manag improv compani
weighted-averag market growth rate wamgr come three year current
valuat target price base ebitda bil slightli higher
trade multipl reflect growth driver above-averag organ growth double-digit ep growth
risk establish pharmaceut epd sustainability/ visibl em fx exposur potenti delays/failur product
initi coverag outperform rate target price
deliv diversifi growth substanti margin improv expect acceler market-weight growth
like one steepest margin improv ramp univers bp next four five year
heel increas expect
out-performance rise estim watchman bil market like remain
provid
hsd dd growth across key market includ afib neuromodul endoscopi tavr transcathet
improv capit structur access cash drive increas run rate tuck-in prior
three year
consist execut out-performance vs expect aid part diversifi portfolio mix high-growth
growth market estim reach bil total key growth market track view
grow compound-annual-growth-rate bil expect portfolio larger core busi icd pacemak
coronari stent grow slowli although continu drive signific cash flow compani
improv access seri larg cash outlay legal settlement ir tax disput access
free cash flow oper strateg purpos improv significantli perspect
expect cash-per-share prior two three year
valuat target price base ebitda bil roughli in-lin current multipl
ntm ebitda risk key product delay failur progress compani long-term plan goal potenti new
litig regulatori qualiti issu
receiv product pleas specifi credit suiss contact email call
initi coverag outperform rate target price
even high-qual hit rough patch sometim difficult expect get back track
believ attract price high-qual turnaround stori expect outperform univers driven
fundament recov investor confid
margin expans improv growth disciplin deliv bp margin improv sinc
track deliv anoth bp bil plan growth new product
view driven margin expans growth profil improv patient disciplin approach strateg
disappoint deliveri busi issu initi misdiagnos result slower growth slightli
longer resolut timelin said beat consensu ep estim rais ep guidanc year
revis long-term organ sale growth outlook believ achiev
potenti beatabl ex-m
new product multipl geographi plan year launch would span six major busi
line plan bil focus deliveri renal pharma near term expect
stabil suppli volum nutrit large-volum parenter array on-going new product launch
 europ japan drive continu solid execut share perform
valuat target price base ebitda bil in-lin current multipl
impli maintain price-to-earnings ntm also consist current level risk includ key product
delay failur progress lrp goal growth margin potenti new litig regulatori qualiti issu
initi coverag under-perform rate target price
share loss erod knee revenu solut remain year away zimmer biomet larg profit knee busi
lost bp market share past four year expect compani lose anoth
bp end given concentr total joint hip knee heavi debt burden net
debt/equ scarciti effect turnaround option near term expect under-perform univers
next month
daunt challeng could push turnaround beyond refil product pipelin take time robot surgeri
platform take year develop launch mako launch year ago prune less-profit product line
might normal make sens case vast major busi line core musculoskelet
devic franchis hip knee sport med extrem trauma import reach debt-leverag goal
absent major divestitur rais capit expect make acquisit signific size
owe debt load cash constraint
organ growth slow stock rerat higher discount valuat rel large-cap comp
attract investor believ challeng face compani fulli discount stock current
level remain rel uniqu within ms trade averag discount
valuat target price base ebitda bil reflect expect share
loss declin organ growth put downward pressur valuat current ntm ebitda risk
rate faster-than-expect resolut suppli issu faster-than-expect remedi fda warn
letter better-than-expect uptak rosa
receiv product pleas specifi credit suiss contact email call
initi coverag outperform rate target price
robot surgeri improv spine growth drive higher robot surgeri rs disrupt bil spine
market one two compani lead charg addit signific commerci impact
robot relat pull-through implant new product improv rep retent product also help drive
share gain spine market one highest convict outperform name recommend
stock current level
sustain ebitda margin growth record ebitda margin distinguish
among smid-cap comp averag posit ebitda estim
core ebitda margin actual bp reinvest growth program robot
trauma ou expans margin profil disciplin reinvest model along brisk pace
innov product launch help compani deliv above-market growth year
expect chang
unfold robot surgeri stori could drive multipl higher rebound valuat
mid- upper teen hard miss howev stock trade slightli high-growth high-margin
comp sale growth ebitda margin includ
rs continu ramp could see upsid target multipl
valuat target price base project ebitda bil trade one turn
current multipl ntm ebitda risk includ key product delay unexpect volum declin spine
market potenti new litig regulatori qualiti issu
initi coverag outperform rate target price
invest improv growth new leader take reign believ innov disrupt forc
minim invas spine surgeri turn corner challeng deliv solid growth
 core spine busi vs led compani new puls advanc surgic technolog offer
new product flow improv wind back manag opt make invest support
continu improv sale growth despit ceo transit addit invest rais
investor concern relat long-term margin goal manag indic commit remain
intact expect new ceo posit impact view attract recommend stock
new ceo help maintain extend intens core spine busi back share-gain
mode recent appoint ceo chri barri posit impact busi owe extens
commerci experi large-scal oper like growth busi like advanc energi franchis
pulse-not attract altern platform unveil nass septemb integr
advanc surgic technolog one stack importantli add surgic navig hospit yet readi
robot even one puls provid image-guid navig significantli reduc x-ray
valuat target price base ebitda mil multipl roughli in-lin
stock current trade multipl risk competit pressur larger spine manufactur robot surgeri system
key product delay failur progress long-term goal potenti new litig regulatori qualiti issu
receiv product pleas specifi credit suiss contact email call
initi coverag outperform rate target price
flow margin turn posit high-growth ortho pure-play appear well posit gener
improv cash flow posit oper margin improv ebitda margin manag
period substanti oper challeng includ chang distribut late came
heel litigation- financing- relat overhang given market-lead shoulder busi highli
differenti expand regen biolog product line augment realign lower-extrem distribut network
show sign reacceler best-in-class manag team view turn point margin cash
flow opportun period buy
market-lead shoulder franchis product pipelin remain robust despit challeng lower extrem foot
ankl market-lead upper extrem portfolio shoulder augment
regen medicin franchis deliv mid- high-teen growth respect inject formul
augment regen bone graft also approv june launch augment growth
hope
addit growth driver improv lower-extrem sale product launch prostep perform
revers shoulder cartiva acquisit boost ntm growth
valuat target price base ev/sal multipl estim bil includ
mil sale financ cartiva multipl stock current multipl ntm sale reflect
expect continu out-performance risk salesforc product issu key product delay failur progress
long-term goal potenti new litig regulatori qualiti issu
initi coverag outperform rate target price
execut issu creat buy opportun recent misstep top-lin miss rattl investor confid
rerat stock view two signific issu mil manag transitori vs anyth
resembl crack foundat diversifi smidcap growth stori given reset estim
recov growth affect area next two three quarter view attract current level
expect stock outperform univers next month
minor hitch codman integr ott sale realign codman integr ahead plan
pocket sale weak emerg late relat day region yet fulli control account
mil miss ortho miss disappoint overli optimist expect
recent hire sale rep usual take least six nine month ramp said mil total
estim reset expect issu work way stock come quarter
regen cusa clariti busi remain solid addit intermediate- long-term benefit
expand scale global reach driven codman deal core high-valu busi like cusa clariti ultrason
ablat system compani broad regen franchis continu deliv solid growth
grow doubl digit expect continu growth go forward
valuat target price driven adjust ebitda estim mil slightli current
valuat ntm ebitda in-lin three-year averag ev/ebitda multipl risk product delay
failur progress long-term goal potenti new litig regulatori qualiti issu
receiv product pleas specifi credit suiss contact email call
initi coverag outperform rate target price
sustain market leader deliv double-digit total return assembl attract portfolio emerging-
high-growth busi organ via tuck-in deal grow approach bil annual
complement compani market-lead franchis cardio surgic diabet spine brain therapi
wide-rang capabl clinic call point relationship broad market footprint global distribut
reach uniqu posit identifi acquire/develop execut innov growth opportun support
sustain growth mix attract total return sharehold view attract recommend stock
current level
growth busi contribut growth estim emerging- high-growth busi
transcathet heart valv robot surgeri implant monitor diabet pumps/monitor leadless
pacemak contribut sale growth year despit current
total sale busi scale manag continu invest strateg see deliv overal
long-term sustain growth
bandwidth tuck-in increas margin target achiev given bulk covidien cov integr
complet improv access global cash flow expect activ front oper
margin approach also view target bp annual increas achiev combin mix
effici program
valuat target price base ebitda bil in-lin stock current trade
multipl ntm ebitda risk includ key product delay failur progress long-term goal growth margin
potenti new litig regulatori qualiti issu
initi coverag outperform rate target price
time tavr market leader ew one highest-convict idea view size
long-term tavr market strength posit disrupt market underappreci street
primari driver stock least come two three year longer expect low-risk lr
trial success march estim indic approxim doubl ew
offset potenti impact new competit next two three year volatil potenti
everyon believ ew significantli outperform univers next month recommend
stock current level
ew lead market third- fourth-gener system make compani hard catch believ new first-
second-gener tavr system face domin clinic matur tavr portfolio ew broader
indic includ younger lr patient largest fastest-grow segment market come three
five year expect reach market respect addit
potenti limit limit high-risk patient patient ew also like continu lead
new tavr center typic start proven market leader
view mitral-rel concern buy opportun mitral repair replac import lt
opportun structur heart repres sale estim
therefor view mitral-rel concern buy opportun ew
valuat target price base ebitda estim bil ew current
multipl ntm ebitda risk includ key product approv delay unexpect chang coverag tavr
greater-than-expect share loss potenti new litig regulatori issu
receiv product pleas specifi credit suiss contact email call
initi coverag outperform rate target price
high-growth med-tech portfolio back mako robot surgeri rs platform demonstr
disrupt power orthopaed help captur bp share knee market sinc integr
compani expect compani take anoth bp share well substanti potenti
share gain spine extrem project combin market mako inclus robot place
implant bil alon
sustain share-gain power rs ortho still underappreci instal base robot
ww repres entrench sustain competit advantag strong adopt reach
total knee implant estim vs year ago believ regulatori approv
 navig bone resect surgic applic hip knee partial knee ip portfolio haptic
sensor make platform hard catch
success robot surgeri platform warrant premium valuat rs ortho spine demonstr
commerci potenti mako mazor pull implant share
system may potenti creat even disrupt valu pound pound platform target
less implant-driven specialti like gener surgeri therefor view premium large-cap diversifi peer
warrant ntm ebitda vs averag pleas also see sum-of-
valuat target price base ebitda bil multipl roughli in-lin
current multipl ntm ebitda risk execut issu relat recent acquisit key product delay failur
progress lt goal chang competit landscap robot surgeri potenti new litig regulatori qualiti
prolong courtship closer fruition rais target price
updat deal term embraer formal term commerci aerospac jv assum
ownership embraer commerci jet servic portfolio headlin enterpris valu jv rais
account separ cost tax oper expens compani expect receiv
net proce sizabl portion like paid sharehold special dividend cost lower
forecast ba erj share save equal deal also extend put option protect erj next
ten year put option valu deal price adjust inflat revert market price lock-up
period compani expect recogn synergi commerci jv addit save
defens bizjet
ip concern histor cautiou possibl ip conflict though management appear take step limit
potenti technolog transfer jv sole respons develop aircraft seat brazilian
regul limit abil manipul spend
step brazilian govern need approv term within day receiv propos expect
rel straightforward process current incom administr taken favor
stanc deal still expect close subject customari close condit approv
valuat light revis deal term rais target price longer discount
estim estim unchang forecast adjust minor mainten
model yet incorpor creation jv
risk includ inabl close jv slowdown commerci oe cycl difficulti integr asset cultur across
receiv product pleas specifi credit suiss contact email call
 plenti afraid use rais estim
result slightli better consensu despit increment fx headwind licens ahead expect
cloud/support line constant currenc revenu guidanc street estim full year doubl digit
constant currenc ep growth reiter reacceler saa book reinforc belief
posit cloud erp maintain outperform rate tp given erp opportun durabl
sustain db
total non-gaap softwar revenu y/i cc slightli consensu despit fx headwind
driven better expect licens revenu gross margin oper margin slightli consensu
estim non-gaap ep compar though benefit lower share count tax rate ocf
adjust tax payment street exclud one-tim y/i
like licens rev exceed expect ecosystem y/i cc line despit tougher
compar saa net book acceler cloud erp fusion netsuit erp could grow close
next year record saa gm busi scale buy-back quarter row aggress
expect continu remain author
like less support cloud servic revenu impli iaas/paa still drag cloud growth databas
ecosystem low singl digit deceler mid-singl digit though busi lumpi databas option
y/i softwar gm continu impact iaas/paa gm still declin op incom growth
deceler flat y/i cc buy-back larger contributor ep growth target vs prior expect
om guidanc expect
valuat revis revenue/ep tp base dcf
analysi impli ev/ufcf risk includ competit cloud failur execut
brick lower estim target price
lower guid consist channel check yesterday green brick announc expect
ep current expect rise afford concern caus hesit among buyer alongsid
heighten competit line channel check indic declin price inventori led
buyer adopt wait-and-se approach specif seen increas incent back half
year green brick primari market dalla atlanta builder look off-set normal activ level advers
weather rain texa especi earlier quarter compound season approach end
year although mortgag rate come recent peak note rang outcom sell season
widen back uncertainti surround buyer appetit broader macro
revis ep estim target price reflect updat guidanc revis model adjust estimate
drop ep drop turn target price base
forward adj book valu
thesi intact maintain neutral rate oper larg focus two nation top hous market look
green brick leverag divers product offer drive top-lin growth said suppli constraint labor
lot inflat persist expect margin increasingli pressur given expect
moder demand stock limit float believ green brick valuat properli captur risk/reward
profil maintain neutral rate
valuat tp forward adj book valu estim vs peer average risk lack geograph
diversif rise rate
receiv product pleas specifi credit suiss contact email call
despit intra-day weak continu rate stock under-perform believ grind lower
week month come market discount anoth potenti neg catalyst incom centuri
integr digit experi act-cal among thing acceler use electron signatur across
feder govern record manag revenu feder govern materi driver
revenu believ bill-feder opportun key focu area irm-coupl acceler volum
declin due revenu manag strategi like contribut underwhelm guidanc view
continu rate stock under-perform see neg estim revisions-on slow intern storag growth
coupl multipl compression-press stock
centuri integr digit experi act idea -anoth unexpect volum headwind beyond
legisl intend modern feder agenc websit support use mobil devic transit away paper-
base form in-person transact modern centuri digit govern experi
digit govern process elimin paper-each execut agenc promot digit public-fac
servic transit digit paper-bas form among initi
use electron day date enact need submit plan increas use electron
impli ev/ebitda compar yr rang averag multipl fair-if
high-a discount grow capit need organ volum declin rise rate especi given refinanc
respect risk normal volum trend return consist
vision announc robust capit alloc plan
dividend increas repurchas author market close monday announc board
director declar increas quarterli dividend per share annual current share
count well fresh share repurchas author replac program approv last decemb
think sharehold like take posit view toward news particularli aggress dividend hike
underscor manag confid busi compani also announc repurchas
share roughli half author come slightli estim year
like set hefti particularli recent weak share continu note howev pend erj
deal schedul close could weigh repurchas near time deal close manag expect
share repurchas resum januari new author repurchas occur next
receiv product pleas specifi credit suiss contact email call
look driver upsid upcom investor commun meet
bottom line perhap common question receiv investor recent upsid
may come stock coverag significantli outperform
market near record high may get answer question least wednesday
invest commun meet base compani histor practic expect compani initi guid
conserv look beat rais go year spend time discuss recent
strong perform key market product highlight import line extens opportun mid-lat stage
pipelin asset could drive growth beyond fairli robust expect investor alreadi
initi guidanc like conserv examin chang lilli guidanc year
guidanc fare actual report ep year end analysi suggest initi guidanc tend
conserv would go top-line
bottom line year expect similar approach compani even stock re-rat
believ initi guidanc like bracket consensu rev ep base
convers lilli investor relat group expect addit long-term guidanc beyond
compani alreadi provid expect detail think pharma busi
stand-alone exclud elanco
expect limit new clinic data wednesday also larg expect review previous disclos late-stag clinic
data deeper discuss pipelin opportun across compani key therapeut area diabet
get detail tirzepatid phase program new data phase titrat studi detail
trulic rewind data wait ada june
incom ceo provid perspect prioriti ahead take top role
bottom line attend lunch host sell-sid analyst soon-to-b ceo albert bourla
opportun get know bourla well year variou meet host
help gain perspect see top prioriti prepar take leadership one
expect smooth transit contrast ceo transit histori appear one rel
seamless given bourla ian read leadership team state lunch ian vision vision
compani outlook markedli differ read becam ceo howev given approach period
compani return growth oppos period signific patent expiri revenu declin
read navig
bullish outlook industri strong demograph trend continu scientif advanc leav bourla excit
futur pharma industri opportun china particular rais multipl time
lunch given volum grow exponenti market second largest behind us
question around drug price remain obviou headwind compani industri deal
pressur time continu propos pro-innov pro-pati measur help address
receiv product pleas specifi credit suiss contact email call
beyond parti line cfo transit
cs view caught yesterday announc cfo michael schlotman transit
advisori role april follow retir decemb serv cfo sinc
schlotman invest commun primari conduit thing kr approach retir age
howev common refrain investor meet recent year key take press releas
subsequ convers follow
ye kpf altern profit stream fact kr chosen intern promot gari millerchip come
person financ kpf key altern profit stream go forward squar trend direct
compani head wherea data limit regard kpf financi role achiev kr ebit guid
materi post acceler double-digit profit growth rate past year see figur
interestingli millerchip lead kr side kroger-walgreen partnership increment indic
relationship eventu pharmaci sale
one guid would surpris see investor express constern around cfo respons
aggress guidanc leav deliveri plan schlotman howev like respons
guidanc given earn earli march continu see potenti upsid low consensu
expect embed ebit growth year-over-year
restock kroger offici intact guidanc conclus restock kroger target risk
chang announc cfo transit run contrari offici messag certainli
commun regard chang plan chang may come note restock kroger remain
primari driver execut long-term incent compens
us card novemb trust loss modestli m/m better histor
loss slightli better season card trust loss rate six largest issuer novemb
bp m/m better averag m/m increas bp novemb bp y/i delinqu
averag bp m/m bp y/i slightli wors averag m/m increas bp
net loss bp m/m bp m/m bp m/m bp m/m bp m/m
flat note trust credit data gener volatil manag perform trust
contain portion manag loan
link month company-specif card data piec
growth continu novemb credit qualiti stabl
synchroni monthli data nco in-line dq modestli vs recent trend
receiv product pleas specifi credit suiss contact email call
consum credit qualiti master trust macroeconom data updat
credit card issuer master trust post monthli novemb updat today look
america jpmorgan master trust see detail herein month-to-month delinqu loss rate up-w
continu expect modest manag lift loss rate credit cost normal specif account portfolio
season mix shift earn estim emb gradual uptick consum loan credit card loss rate
year progress next current low level consum leverag unemploy remain net posit core
novemb monthli master trust detail america master trust portfolio loss rate increas month month
delinqu rate rel averag loss rate still delinqu rate
citi master trust report month month increas loss rate month month
increas delinqu rate rel averag loss rate delinqu rate
jpmorgan report master trust loss rate novemb increas month month delinqu
rate basi point rel averag loss rate delinqu rate
detail herein comparison master trust trend report portfolio result
debt servic employ underscor solid macro backdrop consum net charge-off consum loan
account cs larg cap bank total net charge-off -- health consum critic
manag bank aggreg credit cost herein detail cs larg cap bank consum loan net charge-
rate histori well consum macroeconom data point close monitor specif consum
debt servic burden unemploy trend continu low support confid health
import master trust detail herein bank issuer master trust repres
aggreg credit card outstand still monthli data remain good direct consist indic portfolio
qualiti worth keep eye
refer reader specialti financ analyst mosh orenbuch note card novemb trust loss modestli m/m
better histor
also refer reader note larg cap bank move cycl -- -no worri sight loss rate
stabl
novemb pet adopt slow accord pethealth inc lead provid manag softwar anim shelter
north america yoy growth pet adopt across anim welfar organ essenti flat novemb
slightli experi octob speci felin adopt rose canin adopt drop
note averag price canin veterinari visit higher felin visit accord
adopt anim shelter repres new pet acquisit euthanasia invers correl pet demand
declin novemb
veterinari prescript util rise accord monthli metric iqvia adjust total script prescrib
vet increas novemb strongest trend sinc decemb importantli metric continu track well
ahead human prescript experi note veterinari medic dispens veterinari
practic fulli captur data
anim health read-through pet adopt prescript trend indic overal pet demand offer
baromet perform anim health coverag univers includ zoeti us companion anim sale
compani continu view anim health sector attract altern health care
invest particularli tumultu convent human healthcar backdrop remain posit bias
zoeti industri leader elanco guidanc call tomorrow note
receiv product pleas specifi credit suiss contact email call
 agenc spend advertis deceler below-trend growth y/i novemb
telecom media retail consum electron drag
tv flat lose typic share digit average
within tv nation tv softer month
qtd smi nation tv quit close y/i compani roll-up ex-unusu page
given recent forecast updat see updat trend cord cut
advertis better remain comfort estim whether pace firm next
broadcast gain share due sport rate healthi season
cabl lost share due cabl entertain rate declin sustain high level
expect smi accutv data day provid specif confirm see smi correl page
among coverag cb viab new stub ad-expos deriv third
revenu advertis see advertis sensit full report
would note /- chang advertis revenu would impact disney comcast unlev
low end cb discoveri new viacom high end group exposur cours
advertis sensit
continu prefer project develop equip manufactur shape increasingli posit year
renew project develop benefit lower modul price taper import tariff us suppli glut
compress financ spread us tax credit extens secur invest
california rooftop mandat start expand residenti market faster expect declin batteri
storag cost acceler renew adopt cheapest cost electr global democrat parti
hous support pro-renew polici tax credit extens nation renew portfolio standard favor state
renew polici popular support renew among end-consum corpor
stock like residenti solar develop op whose leas model help captur market share
under-penetrated market grow cash gener favor project financ environ like nextera
nextera partner nep op best class renew develop yieldco us
azur power azr op benefit india solar strategi contract growth big fan solar
cell modul manufactur amid suppli glut like spwr-op due focu grow us
residenti commerci solar busi like daqo new energi dq-op cover asia gari zhou
lowest cost produc commodit solar manufactur neutral first solar cost benefit
priced-in jinkosolar jk given suppli glut challeng bloom energi attract technolog
requir prove cost improv
limit growth risk rate invers posit solar develop replac short term financ long-term
project debt lower cost better match contract cash flow potenti reduct electr load growth util
capital-expenditure due market slowdown could delay util renew invest earli see limit impact solar
wind storag demand enjoy strong regul consum corpor support residenti solar attract
homeown cheaper retail electr cost state though could see uptick leas busi
cash sale declin catalyst itc safe harbor plan ca rooftop mandat partnership
surpris factor better expect china solar target gw posit solar modul price
manufactur neg solar develop us withdraw import solar import posit develop
manufactur neg potenti democrat bill indefinit extend renew tax credit
sunset posit stand-alone tax credit batteri storag product posit retrofit demand
receiv product pleas specifi credit suiss contact email call
infrastructur action egress enb investor day midstream thought
thought last week marque event enbridg inc enb investor day touch upon gamut
issu given big north american footprint perspect critic area day limit
face liquid egress western canadian clear silver bullet deal pipelin limit face
western canada howev believ timelin opportun larg around enb system complet
appreci figur show enb option increas amount volum leav western canada last
major week energi infrastructur market major area convers revolv around egress altern
invest midstream space link report includ ride rail difficult differenti canadian
crude conundrum midstream momentum horizon investor day outlook difficulti opportun investor
major potenti area interest ontario power market resolut labour strike ontario
power gener major union power worker union press releas among other press releas
receiv product pleas specifi credit suiss contact email call
headlin price previou day close unless otherwis note
compani mention price dec
america corp outperform tp
